AI Structural Biology Network
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1
The phase 3 results show improvements in daily function, cognition and nighttime sleep
Takeda’s zasocitinib demonstrates positive results in plaque psoriasis
Around 64 million people worldwide live with psoriasis
BMS, Macmillan and 11 NHS Trusts publish report on cancer treatment prehabilitation
The report shows how prehabilitation can improve patient experience while alleviating capacity pressures
BMS acquires Orbital Therapeutics in $1.5bn deal
The deal includes several next-gen cell therapy candidates for autoimmune diseases
BMS, Takeda and Astex join AI training consortium
The initiative focuses on training AI models to aid in drug discovery and development
Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma
The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma
Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP
The enzyme replacement therapy is now the first treatment approved in the UK for this patient population
Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma
The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication
BMS receives NICE recommendation for immunotherapy combination in colorectal cancer
Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year
BMS receives FDA approval for immunotherapy combination in liver cancer
Around 42,240 people are expected to be diagnosed with liver cancer in the US this year
BMS granted FDA approval for immunotherapy combination in colorectal cancer
More than 154,000 cases of the disease are expected to be diagnosed in the US this year